Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial
Crossref DOI link: https://doi.org/10.1007/s10549-014-3189-y
Published Online: 2014-11-06
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Yardley, Denise A.
Raefsky, Eric
Hainsworth, John D.
Burris, Howard A. III
Priego, Victor
Inclan, Alejandro
Text and Data Mining valid from 2014-11-06
Article History
Received: 13 August 2014
Accepted: 30 October 2014
First Online: 6 November 2014